CN104138634B - 递送抗偏头痛化合物的透皮方法和系统 - Google Patents
递送抗偏头痛化合物的透皮方法和系统 Download PDFInfo
- Publication number
- CN104138634B CN104138634B CN201410110715.2A CN201410110715A CN104138634B CN 104138634 B CN104138634 B CN 104138634B CN 201410110715 A CN201410110715 A CN 201410110715A CN 104138634 B CN104138634 B CN 104138634B
- Authority
- CN
- China
- Prior art keywords
- patch
- purposes
- triptan
- delivery
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000012384 transportation and delivery Methods 0.000 title claims abstract description 82
- 230000002460 anti-migrenic effect Effects 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title abstract description 48
- 150000001875 compounds Chemical class 0.000 title abstract description 17
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical class CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 claims description 126
- 238000011282 treatment Methods 0.000 claims description 68
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 claims description 62
- 229960003708 sumatriptan Drugs 0.000 claims description 61
- 238000002360 preparation method Methods 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 21
- 206010015150 Erythema Diseases 0.000 claims description 19
- 231100000321 erythema Toxicity 0.000 claims description 18
- 206010019233 Headaches Diseases 0.000 claims description 9
- 231100000869 headache Toxicity 0.000 claims description 9
- 241000283073 Equus caballus Species 0.000 claims description 8
- 208000002193 Pain Diseases 0.000 claims description 7
- 239000011469 building brick Substances 0.000 claims description 7
- 230000005611 electricity Effects 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 7
- 239000011701 zinc Substances 0.000 claims description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 6
- 238000003860 storage Methods 0.000 claims description 6
- 229910052725 zinc Inorganic materials 0.000 claims description 6
- 239000000017 hydrogel Substances 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 4
- 230000002040 relaxant effect Effects 0.000 claims description 3
- 208000006561 Cluster Headache Diseases 0.000 claims description 2
- 229910000635 Spelter Inorganic materials 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 230000001314 paroxysmal effect Effects 0.000 claims description 2
- 230000002085 persistent effect Effects 0.000 claims description 2
- 230000002269 spontaneous effect Effects 0.000 claims description 2
- 229960005137 succinic acid Drugs 0.000 claims description 2
- 230000009969 flowable effect Effects 0.000 claims 1
- 238000010850 salt effect Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 description 43
- 239000000203 mixture Substances 0.000 description 22
- 238000002347 injection Methods 0.000 description 20
- 229940090044 injection Drugs 0.000 description 20
- 239000007924 injection Substances 0.000 description 20
- 238000009472 formulation Methods 0.000 description 17
- 238000002665 ion therapy Methods 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 230000036765 blood level Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000011160 research Methods 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 12
- 229940125684 antimigraine agent Drugs 0.000 description 8
- 239000002282 antimigraine agent Substances 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 208000019695 Migraine disease Diseases 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 238000013461 design Methods 0.000 description 7
- 238000012377 drug delivery Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 206010027599 migraine Diseases 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 6
- 230000002045 lasting effect Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000002411 adverse Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 5
- 238000012385 systemic delivery Methods 0.000 description 5
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 229960002133 almotriptan Drugs 0.000 description 4
- 229960002472 eletriptan Drugs 0.000 description 4
- OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 description 4
- 229960002284 frovatriptan Drugs 0.000 description 4
- SIBNYOSJIXCDRI-SECBINFHSA-N frovatriptan Chemical compound C1=C(C(N)=O)[CH]C2=C(C[C@H](NC)CC3)C3=NC2=C1 SIBNYOSJIXCDRI-SECBINFHSA-N 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 229960000425 rizatriptan Drugs 0.000 description 4
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 229960001360 zolmitriptan Drugs 0.000 description 4
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- -1 caffeine Compound Chemical class 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 239000007935 oral tablet Substances 0.000 description 3
- 229940096978 oral tablet Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000004567 concrete Substances 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 2
- 229960003727 granisetron Drugs 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000000952 serotonin receptor agonist Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- PIFPCDRPHCQLSJ-WYIJOVFWSA-N 4,8,12,15,19-Docosapentaenoic acid Chemical class CC\C=C\CC\C=C\C\C=C\CC\C=C\CC\C=C\CCC(O)=O PIFPCDRPHCQLSJ-WYIJOVFWSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000010541 Familial or sporadic hemiplegic migraine Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000027109 Headache disease Diseases 0.000 description 1
- 206010019476 Hemiplegic migraine Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101000905241 Mus musculus Heart- and neural crest derivatives-expressed protein 1 Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229960004833 dexamethasone phosphate Drugs 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003989 dielectric material Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000009429 electrical wiring Methods 0.000 description 1
- 238000004070 electrodeposition Methods 0.000 description 1
- 238000005370 electroosmosis Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 235000021191 food habits Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 208000001288 gastroparesis Diseases 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- 229940040452 linolenate Drugs 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-M linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC([O-])=O DTOSIQBPPRVQHS-PDBXOOCHSA-M 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 229960005254 naratriptan Drugs 0.000 description 1
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 239000007898 rapid-disintegration tablet Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 108010068072 salmon calcitonin Proteins 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- SDLBJIZEEMKQKY-UHFFFAOYSA-M silver chlorate Chemical compound [Ag+].[O-]Cl(=O)=O SDLBJIZEEMKQKY-UHFFFAOYSA-M 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- 229940005127 sumatriptan 50 mg Drugs 0.000 description 1
- 229940097432 sumatriptan injection Drugs 0.000 description 1
- 229960000658 sumatriptan succinate Drugs 0.000 description 1
- PORMUFZNYQJOEI-UHFFFAOYSA-N sumatriptan succinate Chemical compound OC(=O)CCC(O)=O.CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 PORMUFZNYQJOEI-UHFFFAOYSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N trimethylxanthine Natural products CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Electrotherapy Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79181906P | 2006-04-13 | 2006-04-13 | |
| US60/791819 | 2006-04-13 | ||
| US81413106P | 2006-06-16 | 2006-06-16 | |
| US60/814131 | 2006-06-16 | ||
| CN200780022405.3A CN101472644B (zh) | 2006-04-13 | 2007-04-12 | 递送抗偏头痛化合物的透皮方法和系统 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200780022405.3A Division CN101472644B (zh) | 2006-04-13 | 2007-04-12 | 递送抗偏头痛化合物的透皮方法和系统 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104138634A CN104138634A (zh) | 2014-11-12 |
| CN104138634B true CN104138634B (zh) | 2016-09-07 |
Family
ID=38610170
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410110715.2A Expired - Fee Related CN104138634B (zh) | 2006-04-13 | 2007-04-12 | 递送抗偏头痛化合物的透皮方法和系统 |
| CN200780022405.3A Expired - Fee Related CN101472644B (zh) | 2006-04-13 | 2007-04-12 | 递送抗偏头痛化合物的透皮方法和系统 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200780022405.3A Expired - Fee Related CN101472644B (zh) | 2006-04-13 | 2007-04-12 | 递送抗偏头痛化合物的透皮方法和系统 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US7973058B2 (enExample) |
| EP (1) | EP2012871A4 (enExample) |
| JP (3) | JP5580042B2 (enExample) |
| CN (2) | CN104138634B (enExample) |
| AU (1) | AU2007238685B2 (enExample) |
| BR (1) | BRPI0709965C2 (enExample) |
| CA (2) | CA2935569A1 (enExample) |
| EA (1) | EA023147B1 (enExample) |
| HK (1) | HK1203867A1 (enExample) |
| IL (1) | IL194553A (enExample) |
| MX (1) | MX2008012922A (enExample) |
| NZ (2) | NZ610790A (enExample) |
| WO (1) | WO2007120747A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA023147B1 (ru) * | 2006-04-13 | 2016-04-29 | Тева Фармасьютикалс Интернешнл Гмбх | Трансдермальный пластырь для лечения мигрени |
| ES2563061T3 (es) * | 2008-04-28 | 2016-03-10 | Zogenix, Inc. | Nuevas formulaciones para el tratamiento de la migraña |
| US8155737B2 (en) | 2008-06-19 | 2012-04-10 | Nupathe, Inc. | Pharmacokinetics of iontophoretic sumatriptan administration |
| AU2009259601B2 (en) * | 2008-06-19 | 2014-09-18 | Lts Lohmann Therapie-Systeme Ag | Composition for transdermal delivery of cationic active agents |
| US8366600B2 (en) | 2008-06-19 | 2013-02-05 | Nupathe Inc. | Polyamine enhanced formulations for triptan compound iontophoresis |
| AU2009262967C1 (en) | 2008-06-25 | 2015-12-24 | Fe3 Medical, Inc | Patches and methods for the transdermal delivery of a therapeutically effective amount of iron |
| AU2009335085B2 (en) * | 2008-12-30 | 2015-11-05 | Teva Pharmaceuticals International Gmbh | Electronic control of drug delivery system |
| US8190252B2 (en) * | 2009-02-12 | 2012-05-29 | Incube Labs, Llc | Iontophoretic system for transdermal delivery of active agents for therapeutic and medicinal purposes |
| US9008765B2 (en) | 2009-02-12 | 2015-04-14 | Incube Labs, Llc | System and method for biphasic transdermal iontophoretic delivery of therapeutic agents for the control of addictive cravings |
| US8348922B2 (en) * | 2009-02-12 | 2013-01-08 | Incube Labs, Llc | Method and apparatus for oscillatory iontophoretic transdermal delivery of a therapeutic agent |
| US8961492B2 (en) | 2009-02-12 | 2015-02-24 | Incube Labs, Llc | System and method for controlling the iontophoretic delivery of therapeutic agents based on user inhalation |
| US8821945B2 (en) | 2009-04-25 | 2014-09-02 | Fe3 Medical, Inc. | Method for transdermal iontophoretic delivery of chelated agents |
| WO2010151845A2 (en) * | 2009-06-26 | 2010-12-29 | Incube Labs, Llc | Corrosion resistant electrodes for iontophoretic transdermal delivery devices and methods of use |
| EA201270227A1 (ru) * | 2009-08-10 | 2012-10-30 | Нюпэф Инк. | Способы ионофоретического лечения тошноты и мигрени |
| WO2011044175A2 (en) | 2009-10-06 | 2011-04-14 | Incube Labs, Llc | Patch and patch assembly for iontophoretic transdermal delivery of active agents for therapeutic and medicinal purposes |
| WO2011046927A1 (en) * | 2009-10-13 | 2011-04-21 | Nupathe,Inc. | Transdermal methods and systems for the delivery of rizatriptan |
| US8685038B2 (en) | 2009-12-07 | 2014-04-01 | Incube Labs, Llc | Iontophoretic apparatus and method for marking of the skin |
| WO2011100376A2 (en) * | 2010-02-10 | 2011-08-18 | Incube Labs, Llc | Methods and architecture for power optimization of iontophoretic transdermal drug delivery |
| WO2012025239A1 (en) | 2010-08-27 | 2012-03-01 | Grünenthal GmbH | Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators |
| AR082732A1 (es) | 2010-08-27 | 2012-12-26 | Gruenenthal Gmbh | 2-oxiquinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3 |
| AU2012230701B2 (en) | 2011-03-24 | 2016-09-29 | Incube Labs, Llc | System and method for biphasic transdermal iontophoretic delivery of therapeutic agents |
| US9744353B2 (en) | 2012-11-14 | 2017-08-29 | Teva Pharmaceuticals International Gmbh | Detection of presence and alignment of a therapeutic agent in an iontophoretic drug delivery device |
| US9918932B2 (en) | 2016-02-19 | 2018-03-20 | Zosano Pharma Corporation | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines |
| GB2554455A (en) | 2016-09-29 | 2018-04-04 | Feeligreen Sa | Skin treatment device and method for delivery of an active ingredient into the human skin by means of iontophoresis, using an array of electrodes |
| US11660264B2 (en) | 2017-08-23 | 2023-05-30 | Emergex USA Corporation | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches |
| JP7285259B2 (ja) * | 2017-09-12 | 2023-06-01 | エルテーエス ローマン テラピー－ジステーメ アーゲー | イオントフォレーシス用マイクロニードルデバイス |
| US11318292B2 (en) * | 2018-05-28 | 2022-05-03 | Microneedles Inc. | Microneedle patch for transdermal injections |
| US11660265B2 (en) | 2018-06-28 | 2023-05-30 | Emergex USA Corporation | Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches |
| KR20220053554A (ko) | 2019-06-28 | 2022-04-29 | 패스포트 테크놀로지스, 인크. | 트립탄 미세천공 전달 시스템 |
| EP3990063A4 (en) * | 2019-06-28 | 2023-07-05 | PassPort Technologies, Inc. | METHODS AND SYSTEMS FOR CONTROLLING ENERGY DELIVERY TO FILAMENT DEVICES |
| US11364225B2 (en) | 2019-08-21 | 2022-06-21 | Bn Intellectual Properties, Inc. | Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5207752A (en) * | 1990-03-30 | 1993-05-04 | Alza Corporation | Iontophoretic drug delivery system with two-stage delivery profile |
| US5807571A (en) * | 1993-05-06 | 1998-09-15 | Lts Lohmann Therapie-Systeme Gmbh | Transdermal therapeutic systems for administering indole serotonin agonists |
| US5941843A (en) * | 1996-07-12 | 1999-08-24 | Empi, Inc. | Iontophoresis electrode |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4856188A (en) * | 1984-10-12 | 1989-08-15 | Drug Delivery Systems Inc. | Method for making disposable and/or replenishable transdermal drug applicators |
| US4557723A (en) * | 1983-08-18 | 1985-12-10 | Drug Delivery Systems Inc. | Applicator for the non-invasive transcutaneous delivery of medicament |
| US5651768A (en) * | 1983-08-18 | 1997-07-29 | Drug Delivery Systems, Inc. | Transdermal drug applicator and electrodes therefor |
| US5605536A (en) | 1983-08-18 | 1997-02-25 | Drug Delivery Systems Inc. | Transdermal drug applicator and electrodes therefor |
| US4883457A (en) * | 1983-08-18 | 1989-11-28 | Drug Delivery Systems Inc. | Disposable and/or replenishable transdermal drug applicators and methods of manufacturing same |
| US5042975A (en) | 1986-07-25 | 1991-08-27 | Rutgers, The State University Of New Jersey | Iontotherapeutic device and process and iontotherapeutic unit dose |
| US4822802A (en) * | 1987-02-24 | 1989-04-18 | Alza Corporation | Method of fentanly administration for postoperative pain relief |
| US4865582A (en) * | 1987-06-05 | 1989-09-12 | Drug Delivery Systems Inc. | Disposable transdermal drug applicators |
| US5162042A (en) * | 1988-07-05 | 1992-11-10 | Alza Corporation | Electrotransport transdermal system |
| US4927408A (en) * | 1988-10-03 | 1990-05-22 | Alza Corporation | Electrotransport transdermal system |
| DE4014913C2 (de) * | 1990-05-10 | 1996-05-15 | Lohmann Therapie Syst Lts | Miniaturisiertes transdermales therapeutisches System für die Iontophorese |
| WO1995025562A1 (en) | 1992-06-02 | 1995-09-28 | Alza Corporation | Electrotransport drug delivery device |
| DE4314976C1 (de) * | 1993-05-06 | 1994-10-06 | Lohmann Therapie Syst Lts | Transdermale therapeutische Systeme zur Verabreichung von Wirkstoffen, Verfahren zu ihrer Herstellung und ihre Verwendung |
| US5458569A (en) * | 1993-06-08 | 1995-10-17 | Becton Dickinson And Company | Wearable iontophoresis system |
| PH31437A (en) * | 1993-08-27 | 1998-11-03 | Janssen Pharmaceutica Nv | Tontophoretic delivery of an antimigrane drug. |
| US5533971A (en) * | 1993-09-03 | 1996-07-09 | Alza Corporation | Reduction of skin irritation during electrotransport |
| US5697896A (en) * | 1994-12-08 | 1997-12-16 | Alza Corporation | Electrotransport delivery device |
| JPH08317997A (ja) * | 1995-03-17 | 1996-12-03 | Takeda Chem Ind Ltd | 経皮透過方法 |
| US5700481A (en) * | 1995-03-17 | 1997-12-23 | Takeda Chemical Industries, Ltd. | Transdermal drug delivery process |
| IE960312A1 (en) * | 1995-06-02 | 1996-12-11 | Alza Corp | An electrotransport delivery device with voltage boosting¹circuit |
| CN1147329C (zh) * | 1995-06-05 | 2004-04-28 | 阿尔萨公司 | 用于经皮肤电输送芬太尼和苏芬太尼的装置 |
| US6425892B2 (en) * | 1995-06-05 | 2002-07-30 | Alza Corporation | Device for transdermal electrotransport delivery of fentanyl and sufentanil |
| US6216033B1 (en) * | 1996-05-22 | 2001-04-10 | Alza Corporation | Device for transdermal electrotransport delivery of fentanyl and sufentanil |
| US5983130A (en) * | 1995-06-07 | 1999-11-09 | Alza Corporation | Electrotransport agent delivery method and apparatus |
| US6245347B1 (en) * | 1995-07-28 | 2001-06-12 | Zars, Inc. | Methods and apparatus for improved administration of pharmaceutically active compounds |
| US5688232A (en) | 1995-09-28 | 1997-11-18 | Becton Dickinson And Company | Iontophoretic drug delivery device having an improved controller |
| US5968547A (en) * | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| US5882677A (en) * | 1997-09-30 | 1999-03-16 | Becton Dickinson And Company | Iontophoretic patch with hydrogel reservoir |
| JP4290271B2 (ja) | 1998-04-14 | 2009-07-01 | 久光製薬株式会社 | 経皮透過方法 |
| SE9802864D0 (sv) * | 1998-08-27 | 1998-08-27 | Pharmacia & Upjohn Ab | Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder |
| EP1170029B1 (en) | 1999-04-12 | 2009-03-11 | Hisamitsu Pharmaceutical Co., Inc. | Device for iontophoresis |
| US6312716B1 (en) * | 1999-05-10 | 2001-11-06 | Peierce Management Llc | Patch and method for transdermal delivery of bupropion base |
| US6385488B1 (en) | 1999-05-20 | 2002-05-07 | Vyteris, Inc. | Circuits for increasing the reliability of an iontophoretic system |
| US6421561B1 (en) * | 1999-12-30 | 2002-07-16 | Birch Point Medical, Inc. | Rate adjustable drug delivery system |
| SI1307194T2 (sl) * | 2000-07-31 | 2011-07-29 | Nycomed Danmark Aps | Sestavek fentanila za nazalno dejanje |
| US6653014B2 (en) * | 2001-05-30 | 2003-11-25 | Birch Point Medical, Inc. | Power sources for iontophoretic drug delivery systems |
| WO2003032983A1 (en) * | 2001-06-05 | 2003-04-24 | Ronald Aung-Din | Transdermal migraine therapy |
| JP4394444B2 (ja) * | 2001-10-24 | 2010-01-06 | パワー ペーパー リミティド | 活性物質の制御された皮膚内デリバリーのためのデバイス及び方法 |
| EP1478400A1 (en) * | 2002-02-26 | 2004-11-24 | Ortho-McNeil Pharmaceutical, Inc. | Therapy for the treatment of migraine comprising anticonvulsant derivatives and antimigraine agents |
| JP4191951B2 (ja) | 2002-04-25 | 2008-12-03 | ソントル ファルマペプティド | 抗微生物剤投与装置および組立品 |
| CA2512854C (en) * | 2002-06-28 | 2010-02-09 | Alza Corporation | A reservoir for use in electrotransport drug delivery |
| US6745071B1 (en) * | 2003-02-21 | 2004-06-01 | Birch Point Medical, Inc. | Iontophoretic drug delivery system |
| US20040242770A1 (en) * | 2003-04-16 | 2004-12-02 | Feldstein Mikhail M. | Covalent and non-covalent crosslinking of hydrophilic polymers and adhesive compositions prepared therewith |
| US8734421B2 (en) * | 2003-06-30 | 2014-05-27 | Johnson & Johnson Consumer Companies, Inc. | Methods of treating pores on the skin with electricity |
| US20050228336A1 (en) * | 2004-04-07 | 2005-10-13 | Preston Keusch | Electrically assisted lidocaine and epinephrine delivery device having extended shelf-stability |
| UY28935A1 (es) | 2004-06-03 | 2005-07-29 | Alza Corp | Sistema y metodo para la administracion transdermica de un anticoagulante |
| US7537590B2 (en) * | 2004-07-30 | 2009-05-26 | Microchips, Inc. | Multi-reservoir device for transdermal drug delivery and sensing |
| US7856263B2 (en) * | 2005-04-22 | 2010-12-21 | Travanti Pharma Inc. | Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis |
| JP2009509674A (ja) * | 2005-09-30 | 2009-03-12 | Ｔｔｉ・エルビュー株式会社 | 活性物質の全身送達のためのイオントフォレーシス方法及び装置 |
| EA023147B1 (ru) | 2006-04-13 | 2016-04-29 | Тева Фармасьютикалс Интернешнл Гмбх | Трансдермальный пластырь для лечения мигрени |
-
2007
- 2007-04-12 EA EA200802146A patent/EA023147B1/ru not_active IP Right Cessation
- 2007-04-12 MX MX2008012922A patent/MX2008012922A/es active IP Right Grant
- 2007-04-12 AU AU2007238685A patent/AU2007238685B2/en not_active Ceased
- 2007-04-12 NZ NZ610790A patent/NZ610790A/en not_active IP Right Cessation
- 2007-04-12 EP EP07755312.1A patent/EP2012871A4/en not_active Withdrawn
- 2007-04-12 CA CA2935569A patent/CA2935569A1/en not_active Abandoned
- 2007-04-12 NZ NZ596498A patent/NZ596498A/xx unknown
- 2007-04-12 WO PCT/US2007/009000 patent/WO2007120747A2/en not_active Ceased
- 2007-04-12 BR BRC20709965-7A patent/BRPI0709965C2/pt not_active IP Right Cessation
- 2007-04-12 JP JP2009505469A patent/JP5580042B2/ja not_active Expired - Fee Related
- 2007-04-12 CN CN201410110715.2A patent/CN104138634B/zh not_active Expired - Fee Related
- 2007-04-12 CN CN200780022405.3A patent/CN101472644B/zh not_active Expired - Fee Related
- 2007-04-12 CA CA2650412A patent/CA2650412C/en not_active Expired - Fee Related
-
2008
- 2008-07-28 US US12/181,142 patent/US7973058B2/en not_active Expired - Fee Related
- 2008-10-06 IL IL194553A patent/IL194553A/en active IP Right Grant
-
2011
- 2011-05-11 US US13/105,562 patent/US9272137B2/en not_active Expired - Fee Related
- 2011-05-11 US US13/105,585 patent/US8470853B2/en not_active Expired - Fee Related
-
2014
- 2014-07-10 JP JP2014141927A patent/JP5925844B2/ja not_active Expired - Fee Related
-
2015
- 2015-05-06 HK HK15104294.8A patent/HK1203867A1/xx unknown
-
2016
- 2016-02-26 US US15/055,312 patent/US20160317464A1/en not_active Abandoned
- 2016-04-20 JP JP2016084282A patent/JP2016163723A/ja not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5207752A (en) * | 1990-03-30 | 1993-05-04 | Alza Corporation | Iontophoretic drug delivery system with two-stage delivery profile |
| US5807571A (en) * | 1993-05-06 | 1998-09-15 | Lts Lohmann Therapie-Systeme Gmbh | Transdermal therapeutic systems for administering indole serotonin agonists |
| US5941843A (en) * | 1996-07-12 | 1999-08-24 | Empi, Inc. | Iontophoresis electrode |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104138634B (zh) | 递送抗偏头痛化合物的透皮方法和系统 | |
| US7780981B2 (en) | Biosynchronous transdermal drug delivery | |
| Siegel et al. | A unique iontophoretic patch for optimal transdermal delivery of sumatriptan | |
| CN102573489A (zh) | 用离子电渗疗法治疗恶心和偏头痛的方法 | |
| JP5951741B2 (ja) | イオントフォレシスによるスマトリプタン投与の薬物動態 | |
| AU2015203213B2 (en) | Transdermal methods and systems for the delivery of anti-migraine compounds | |
| AU2012261753B2 (en) | Transdermal methods and systems for the delivery of anti-migraine compounds | |
| Bagade et al. | FUNDAMENTAL PRINCIPLE AND APPLICATIONS OF IONTOPHORESIS IN CONTEMPORARY ADVANCEMENT OF DRUG DELIVERY SYSTEM: A CRITICAL APPRAISAL |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1203867 Country of ref document: HK |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160325 Address after: Switzerland Jonathan Applicant after: TEVA PHARMACEUTICALS INTERNATIONAL GMBH Address before: American Pennsylvania Applicant before: NuPathe Inc. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160907 Termination date: 20170412 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1203867 Country of ref document: HK |